Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: A symblepharon is an adhesion between the bulbar and the palpebral conjunctiva and is a manifestation of the loss of conjunctival redundancy. It occurs due to conjunctival scarring, most commonly resulting from trauma or chronic inflammation. Vision can be affected either if the symblepharon is present along with primary keratopathy and limbal stem cell deficiency, or if it is extensive leading to secondary corneal involvement. There is currently no medical treatment for symblepharon, nor can its occurrence be fully prevented. Surgical management is often necessary in cases associated with chronic cicatrizing conjunctivitis.
Purpose: This review aims to summarize the etiology, clinical presentation, and management strategies for ocular symblephara. Methods: A comprehensive literature search was conducted using PubMed database, identifying published studies addressing ocular symblephara and their management. Mechanisms of symblephara formation and emerging treatment modalities for prevention of symblephara were also evaluated.
Conclusion: Surgical approaches to symblephara management involve excision of the fibrotic tissue and placement of mechanical barriers or biological tissue substitutes such as amniotic membranes, conjunctival autografts, and oral mucous membrane grafts. Surgical intervention is recommended for symblepharon in cases where cosmesis is a concern, the visual axis is affected, or in extensive cases before procedures such as cataract surgery, limbal stem cell transplantation, or keratoprosthesis surgery, as well as to facilitate scleral contact lens fitting. Management also involves addressing the underlying disease that led to symblepharon formation. The recurrence rate of symblepharon following surgical treatment is higher in eyes with Stevens-Johnson syndrome or mucous membrane pemphigoid compared to those with ocular chemical burns. Further research is needed to explore preventive strategies such as anti-fibrotic agents and potential medical treatment for symblepharon.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/08820538.2025.2519050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Celastrol Activates SIRT1/PGC-1α/Nrf2 Axis to Inhibit Oxidative Damage for Subconjunctival Fibrosis Alleviation.
Invest Ophthalmol Vis Sci
August 2025
Henan Eye Hospital, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, PR China.
Purpose: Subconjunctival fibrosis can lead to symblepharon and recurrent pterygium, seriously threatening vision. Our previous research found that celastrol could inhibit subconjunctival fibrosis. The purpose of this study was to investigate the underlying mechanisms of celastrol-nanomicelles (Cel) in inhibiting subconjunctival fibrosis.
View Article and Find Full Text PDFOcular Complications in stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Comprehensive Review.
Semin Ophthalmol
August 2025
Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis are rare but life-threatening mucocutaneous disorders, primarily triggered by adverse drug reactions. Although systemic manifestations have been extensively studied, ocular involvement remains a major cause of morbidity, often resulting in severe visual impairment or blindness.
Methods: This narrative review synthesizes current evidence regarding the clinical presentation, pathophysiology, and management strategies for ocular complications in SJS/TEN.
Sarcoid conjunctival granuloma responding to biological therapy.
Eur J Ophthalmol
August 2025
Manchester Royal Eye Hospital, Manchester, UK.
IntroductionConjunctival involvement in sarcoidosis typically presents as non-scarring granulomatous inflammation; however, cicatricial conjunctivitis represents a rare and poorly characterised manifestation. There are currently no published reports of sarcoid-related conjunctival granulomas with cicatrising features responding to anti-TNF therapy. We present the first case of biopsy-confirmed conjunctival sarcoidosis with progressive scarring successfully treated with adalimumab after failure of conventional immunosuppression.
View Article and Find Full Text PDFSignal mining and risk analysis of tisotumab vedotin adverse events based on the FAERS database.
Sci Rep
August 2025
Department of Obstetrics and Gynecology, Guangyuan Central Hospital, No.16 Jingxiang Lane, Lizhou District, Guanyuan, Sichuan Province, China.
Tisotumab vedotin (TV), the first antibody-drug conjugate (ADC) targeting tissue factor, was granted approval by the Food and Drug Administration (FDA) for the treatment of recurrent or metastatic cervical cancer. However, its adverse events (AE) are mainly recorded in clinical trials, lacking of real-world data. The FDA Adverse Event Reporting System database was searched retrospectively, and the TV-related AE reports from July 2021 to September 2024 were extracted.
View Article and Find Full Text PDFLong-Term Surgical Outcome of Pterygium Excision and Conjunctival Limbal Autograft: Minimum 11 years Follow-up Study in a Country with High Ultraviolet Exposure.
Clin Ophthalmol
August 2025
Department of Ophthalmology, Hamad Medical Corporation, Doha, Qatar.
Objective: To assess the long-term surgical outcome and complications in patients who underwent pterygium excision with conjunctival limbal autograft at least 11 years after surgery in a country with high ultraviolet light exposure.
Material And Methods: This was a long-term, cross-sectional, observational follow-up study of 15 patients with primary or recurrent pterygium who underwent surgery at King Abdullah University Hospital, Jordan, between June 2005 and June 2012. Data regarding the patients' satisfaction with the results, use of protective sunglasses, and daily sunlight exposure over the long-term period after surgery were collected.